Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | D816V |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | KIT D816V lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 19865100). D816V results in constitutive phosphorylation of Kit, activation of Stat5 signaling (PMID: 19865100, PMID: 18390729), induces mastocytosis and tumor formation in mice (PMID: 21148330) and confers resistance to Kit inhibitors (PMID: 22301675, PMID: 19164557). |
Associated Drug Resistance | Y |
Category Variants Paths |
KIT mutant KIT act mut KIT D816V KIT mutant KIT exon17 KIT D816X KIT D816V |
Transcript | NM_000222.3 |
gDNA | chr4:g.54733155A>T |
cDNA | c.2447A>T |
Protein | p.D816V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017008179 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54733155A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54733167A>T | c.2447A>T | p.D816V | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04910685 | Phase II | Elenestinib | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 1 |